Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"November 13, 2026 2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on . “
data-action=”subscribe”>
Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: A larger proportion of those receiving oral budesonide vs. dupilumab had incident asthma. The budesonide group had a greater number of asthma diagnoses during follow-up vs. the dupilumab group. PHOENIX \u2014 Significantly fewer children with eosinophilic esophagitis receiving dupilumab developed incident asthma than those receiving budesonide, according to findings presented here. Kayla Steinberger \u201cPediatric patients who have allergic diseases are prone to more,\u201d Kayla Steinberger, MD, PhD, resident physician in pediatrics at West Virginia University, told Healio. \u201cWe should consider treating patients holistically and ensure patients have access to the most appropriate treatment.\u201d
Data derived from\u00a0Steinberger K. R052: Early dupilumab treatment for pediatric eosinophilic esophagitis is associated with reduced incident asthma. Presented at: ACAAI Annual Scientific Meeting; Nov. 12-16, 2026; Phoenix.
In a retrospective cohort study presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting, Steinberger evaluated children aged 6 years or younger with eosinophilic esophagitis receiving either dupilumab (Dupixent; Sanofi, Regeneron) or oral budesonide in the TriNetX Research Network from 2016 to 2026 to determine if the incidence of asthma differs by treatment. \u201cDespite strong evidence that childhood allergic illnesses are driven by type 2 inflammation, the type 2 inflammation inhibitor, dupilumab, is not approved for asthma in children until 6 years old,\u201d Steinberger said. \u201cHowever, it is approved for other allergic diseases such as eczema and eosinophilic esophagitis (an allergic disease of the food tube) in infants. \u201cI wanted to see if children treated with dupilumab early in life, before its approval for asthma, had lower risk of an asthma diagnosis,\u201d she continued. Steinberger used propensity scores to match the two groups based on baseline demographics (age, sex) and atopic dermatitis, and this yielded 344 patients in the dupilumab group and 401 patients in the budesonide group. A significantly larger proportion of those receiving oral budesonide vs. dupilumab had incident asthma (16.2% vs. 10.5%; risk difference, 5.7%; P = .022), which corresponded to a higher risk for incident asthma (risk ratio = 1.55; 95% CI, 1.06-2.27). Steinberger also found that the budesonide group had a greater number of asthma diagnoses during follow-up vs. the dupilumab group (mean, 0.743 vs. 0.369 events per patient; P = .028). \u201cI hypothesized that new asthma incidence would be lower because dupilumab would be treating the underlying pathway that would lead to asthma, something oral budesonide would not theoretically do,\u201d she told Healio. \u201cI was, however, surprised that the number of asthma diagnoses per person was also lower in dupilumab treated patients compared to budesonide, as this number represents each time \u2018asthma\u2019 was billed for in medical visits (meaning one patient can have multiple \u2018asthma\u2019 diagnoses),\u201d she said. Moving forward, Steinberger said stronger longitudinal prospective studies are needed. For more information: Kayla Steinberger, MD, PhD, can be reached at kaylajsteinberger@gmail.com. Sources\/Disclosures Source: Steinberger K. R052: Early dupilumab treatment for pediatric eosinophilic esophagitis is associated with reduced incident asthma. Presented at: ACAAI Annual Scientific Meeting; Nov. 12-16, 2026; Phoenix. Reference:
Disclosures:
Steinberger reports no relevant financial disclosures.
Ask a clinical question and tap into Healio AI’s knowledge base.
PubMed, enrolling\/recruiting trials, guidelines
Clinical Guidance, Healio CME, FDA news
Healio’s exclusive daily news coverage of clinical data
Learn more
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on . “
data-action=”subscribe”>
Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Source link<\/p>\n","protected":false},"author":1,"featured_media":4363,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-4362","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts\/4362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4362"}],"version-history":[{"count":0,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts\/4362\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/media\/4363"}],"wp:attachment":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}